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Background: Proteomic studies of the secretome of skeletal muscle cells can help us understand the processes that
govern the synthesis, systemic interactions and organization of skeletal muscle and identify proteins that are
involved in muscular adaptations to exercise, ageing and degeneration. In this systematic review, we aimed to
summarize recent mass-spectrometry based proteomics discoveries on the secretome of skeletal muscle cells in
response to disease, exercise or metabolic stress.
Methods: A literature search was performed in the Medline/Ovid and Scopus electronic bibliographic databases.
Only papers reporting the analysis of the secretome by mass spectrometry were included.
Results: A total of 19 papers met the inclusion criteria for this systematic review. These papers included
comparative analysis of differentially expressed proteins between healthy and unhealthy muscle cells and com-
parison of the secretome of skeletal muscle cells during myogenesis and after insulin stimulation or exercising.
The proteins were separated into several categories and their differential secretion was compared. In total, 654
proteins were listed as being present in the secretome of muscle cells. Among them, 30 proteins were differentially
regulated by physical exercise, 130 during myogenesis, 114 by dystrophin deficiency, 26 by muscle atrophy, 27
by insulin stimulation and finally 176 proteins secreted by insulin-resistant muscle cells.
Conclusions: This systematic review of the secretome of skeletal muscle cell in health and disease provides a
comprehensive overview of the most regulated proteins in pathological or physiological conditions. These pro-
teins might be therapeutic targets or biochemical markers of muscle diseases.1. Introduction
Skeletal muscle accounts for approximately 40% of the total body
weight and contains between 50 and 75% of all body proteins.1 This
organ has many more functions than joint motion by contraction, it has
fundamental participation in immunometabolic processes, as provider of
substrates to immune system and as glucose buffering organ. It storages
important molecules like amino acids and carbohydrates (i.e. glycogen),
and provides the production of heat for body temperature regulation.1
Skeletal muscle architecture is characterized by the arrangement of the




secretome of skeletal musclemature muscles are myocytes. Myocytes are long, tubular cells that
develop from myoblasts to form muscles in a process known as myo-
genesis. There are various specialized forms of myocytes with distinct
properties: cardiac, skeletal, and smooth muscle cells. Skeletal muscle
stem cells (also called skeletal muscle satellite cells) are located between
the sarcolemma and the basal lamina. These quiescent cells are activated
by muscle fiber degeneration or injury and proliferate in myoblasts.
These last proliferate, differentiate and fuse to form multinucleated
myofibers. The connective tissue surrounding the muscle is known as the
epimysium. Another layer of connective tissue called perimysium sur-
rounds the bundles of fibers. Finally, the sarcolemma envelops the singleversity of Liege, Institute of Pathology, level 5, CHU Sart Tilman, 4000, Liege,
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A. Florin et al. Osteoarthritis and Cartilage Open xxx (xxxx) xxxmuscle fiber which has in mean 1 cm in length and 100 μm in diameter.1
The myofiber contains myofibrils which are composed of sarcomeres (the
basic contractile units of skeletal muscle). The sarcomere is composed
mainly by thick (myosin) and thin (actin, troponin and tropomyosin)
filaments that can slide with each other's and lead to contraction of the
muscle.1
Skeletal muscle is an active endocrine organ containing cells that may
communicate in an auto-, para- or endocrine manner thanks to the
secretion of mediators like myokines. Pedersen et al defined myokines as
“cytokines and other peptides that are produced, expressed, and released
by muscle fibers and exert either paracrine or endocrine effects”.2 Beside
myokines, other molecules like proteins, lipids, amino acids, metabolites
and small RNAs secreted by skeletal muscle cells are also involved in cells
communication.3–5 Myokines mediate metabolic regulation, inflamma-
tory processes, angiogenesis and myogenesis.6–9 Myogenesis is the pro-
cess during which the muscle stem cells, or satellite cells, proliferate and
differentiate into mature muscle fibers, or myotubes. This process is
crucial for maintenance and repair of muscle tissue.
Furthermore, myokines are likely to play important roles in the
pathophysiology of diseases like sarcopenia, insulin resistance or type-2
diabetes. The secretory profile of the skeletal muscle cells is changed by
strength and/or endurance exercising.10–13,9 For example, in addition to
its role in inflammation, immune responses and hematopoiesis,
interleukin-6 (IL-6) released by muscles during contraction, influences
lipid and glucose metabolism.14–16
The secretome has been defined by Makridakis et al as the “rich,
complex set of molecules secreted from living cells”.17 The study of the
secretome of skeletal muscle cells may help to understand the processes
that govern synthesis and organization of the skeletal muscle, its relation
with adipose tissue, immune system and could help to identify factors
responsible for metabolic, structural and functional changing in muscle
during aging. In addition, the secretome of skeletal muscle cells could be
a source of biomarkers of muscle disease and source of therapeutic target
for future therapy.
The types of cell cultures most commonly used for secretome analysis
are rat L6 skeletal muscle cells, mouse C2C12 skeletal muscle cells or
primary human skeletal muscle cells.9 Among techniques used to analyse
the secretome of skeletal muscle cells, mass spectrometry is recognized as
the most accurate, due to its specificity and robustness.18 There are two
strategies for spectrometry-based global protein analysis: bottom-up and
top-down proteomics.19–21 Top-down strategies directly analyze intact
proteins while bottom-up proteomics include an enzymatic digestion step
of proteins to analyze the resulting peptides. The bottom-up strategy is
the most often used for global protein analysis, because top-down strat-
egy is more complicated to handle with larger proteins due to their poor
solubility.22 Furthermore, the detection limits and sensitivity of the mass
spectrometer are lower for proteins than for peptides.22 This review focus
only on bottom-up strategies.
The objectives of this paper were to list the proteins identified by
mass spectrometry in the secretome of skeletal muscle cells and to
summarize knowledges on the modification of this secretome in different
experimental and pathological conditions. To our knowledge, this is the
first review covering systematically the literature published in this field.
2. Materials and methods
This review was performed according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A
literature search was performed in two electronic bibliographic data-
bases: Medline/Ovid and Scopus. Regarding the search done on Medline,
a combination of Mesh terms as well as free language was used. Details of
the search terms which included keywords like “secretome”, “secreted
proteins”, “myoblasts”, “skeletal muscle cells”, “skeletal muscle fibers” or
“skeletal muscle satellite cells” were used. The search strategies are
available in the supplementary file 1. Only papers published in English
and reporting the analysis of the secretome of isolated skeletal muscle2
cells or skeletal muscle explants of all species by mass spectrometry were
included. Articles were screened independently by two authors. Sup-
plementary files of all papers were analyzed and relevant data were
included in this review.
3. Results
Using the search strategies given in supplementary file 1, 421 papers
were found from Medline/Ovid database, and 1195 from Scopus. After
eliminating 371 duplicates, 1245 articles were screened. Then, 32 full-
texts were assessed for eligibility. Finally, 19 papers met the inclusion
criteria for this review (fig. 1). In total, 654 proteins were listed in this
systematic review as being present in the secretome of muscle cells
(Table 2). Among them, 30 proteins were differentially regulated by
physical exercise (all upregulated), 130 duringmyogenesis (90 up- and 40
downregulated), 114 by dystrophin deficiency (107 up- and 7 down-
regulated), 26 by muscle atrophy (15 up- and 11 downregulated), 27 by
insulin stimulation (14 up- and 13 downregulated) and finally 176 pro-
teins secreted by insulin-resistant muscle cells (26 up- and 150 down-
regulated). Comparative analysis of differentially expressed proteins
between healthy and unhealthy (Duchenne muscular dystrophy, muscle
atrophy, insulin resistant cells, etc.) skeletal muscle cells were conducted
by different research groups. Comparison of secretome of skeletal muscle
cells after exercising or duringmyogenesis were also conducted. Themain
characteristics of the proteomic studies are listed in Table 1.
3.1. Exercise
Analysis of secretome shows that no proteins are down-regulated and
30 are up-regulated by exercises (fig. 2). Galectin 1, CC motif chemokine
2, serpin C1, superoxide dismutase and cadherin 23 are oversecreted in
exercise-mimicking AMP-kinase agonist 5-aminoimidazole-4-carbox-
amide-1-β-D-ribofuranoside (AICAR)-treated skeletal muscle cells. AICAR
mimics some aspects of exercising. Indeed, AMPK activation blocks
energy-consuming processes and promotes ATP synthesis from glucose
uptake, glycosylation and fatty acid oxidation.
Interestingly, a lot of cytoskeletal proteins are up-regulated during
exercise (9 out 30 proteins). Exercising leads to a rise in actin, vimentin,
vinculin and desmin secretion.29 The desmin is an intermediate filament
protein of the cytoskeleton which stabilizes the sarcomere.41 This protein
is used as a marker of myogenicity because it is prominent in activated
myoblasts and developing or regenerating fibers.28
3.2. Myogenesis
The secretion of 130 proteins are regulated during myogenesis (90
up- and 40 downregulated) (fig. 3). Among those, decorin and biglycan,
two major components of the extracellular matrix, are found to be
elevated in the secretome of skeletal muscle cells. These two small pro-
teoglycans reduce the bioavailability of TGF-β during myogenesis.27,42,43
Considering that TGF-β plays a role in promoting the synthesis of extra-
cellular components, to reduce TGF-β availability leads to a decrease in
extracellular matrix components synthesis. Mimecan (also called osteo-
glycin), a component of the extracellular matrix which is involved in
collagen fibrillogenesis, was found to be decreased in the secretome of
skeletal muscle cells during myogenesis.
Regarding the collagens, most of them are upregulated during myo-
genesis (I (α1), II(α1), V (α1, α3) VI(α1), XI (α1)). Only two collagens are
downregulated (III(α1), XVIII(α1)). This is the contrary for laminins,
which are mostly downregulated during myogenesis (α2, α5, β2).
The Secreted Protein Acidic and Rich in Cysteine (SPARC) is a protein
regulating cell growth through interactions with cytokines and the
extracellular matrix. SPARC is highly expressed in injured muscles and in
muscle cells undergoing development or regeneration.29,44 Studies
contradict one another concerning the regulation of SPARC during
myogenesis.
Fig.1. Preferred reporting items for systematic reviews and meta-analysis (PRISMA) Flow diagram.23 No MS ¼ No Mass Spectrometry.
A. Florin et al. Osteoarthritis and Cartilage Open xxx (xxxx) xxxBeside these extracellular matrix components, numerous cytokines
and growth factors are modulated during myogenesis. C–C motif che-
mokines 2, 7 and 8, the complement C1q or tumor necrosis factor-related
protein 3 and 5 are upregulated. The only ones downregulated cytokines
and growth factors during myogenesis are the follistatin related protein 1
and Insulin-like Growth Factor Binding Protein 2 (IGFBP2).
In addition to its role in ECM components synthesis, TGF-β is a
complex regulator of skeletal muscle development. This protein is regu-
lated in many different ways, for instance by sequestration via latent
TGF-β-binding proteins (LTBPs).27 There is a pronounced increased in the
secretion of TGF-β1, - β2, - β3 during myogenesis. In parallel, LTBP-3 is
modestly enhanced on day 2 but markedly increase on day 5 of myo-
genesis.27 On the other hand, the secretion of Follistatin-like 1 (FSTL1)
decreases during myogenesis.32 FSTL1 is secreted by skeletal muscle cells
and is involved in muscle vascularization and metabolism.45,46,27,47
FSTL1 may be a positive regulator of myogenesis by counteracting TGF- β
signaling pathway.32 This protein may be involved in the early phase of
myogenesis (cell migration, cell-cycle exit, …) since it is more expressed
by myoblasts than myotubes cultures.32
Insulin-like Growth Factors (IGFs) promote differentiation of skeletal
muscle cells.27 They are found increased during myogenesis.27 The
regulation of the IGFs is regulated by IGFBPs in the extracellular envi-
ronment, inhibiting or enhancing the effect depending on cell type and
context. The growth hormone (GH) stimulates the secretion of IGF-1 by
muscles.48 IGF-1 plays essential roles in regeneration and hypertrophy of
the muscles and is also an osteogenic factor.27,49,50 This protein may be
involved in muscle-bone crosstalk.49 During myogenesis, the secretion of
IGF-2 is markedly increased throughout differentiation. The highest level
of IGF-1 is observed at day 2 of differentiation.27 The secretion of IGFBPs
is also modulated during myogenesis. IGFBP2 secretion decreased during3
differentiation process whereas globally IGFBP4 levels increased.27 In
contrast, IGFBP6 or -7 levels were not significantly modified.27 Finally,
contradictory results have been published regarding IGFBP532,37.
Semaphorins are important modulators of neurogenesis,51 organo-
genesis, tumor progression, angiogenesis and immune responses.52
Further, they play an important role in skeletal muscle development.53,54
Semaphorin 3A, 3D, 3E and 6A are secreted by skeletal muscle satellite
cells and are up-regulated at the early phase of muscle differentia-
tion.27,55 Concerning the secretion of semaphorin 7A, contradictory re-
sults exist.27 According the study, this protein was found up- or
downregulated during myogenesis.18,37
MMP2 is up-regulated during myogenesis, and the highest level is
reached during early phase of the differentiation process.27 The metal-
loproteinase inhibitor 2 (TIMP2) inhibits MMPs40 and also decreased
myogenin expression, leading to an inhibition of myogenesis.40
3.3. Dystrophin deficiency
A total of 114 proteins were regulated by dystrophin deficiency (107
up- and 7 downregulated). Approximately twice as much proteins were
secreted by dystrophin deficient (mdx) vs wild-type (WT) skeletal muscle
cells and most of the oversecreted proteins were cytosolic. In addition,
fibronectin was found in higher amount in the conditioned media of mdx
muscle cells.34
3.4. Muscle atrophy
Fifteen proteins were oversecreted during muscle atrophy and 11
were under-secreted. Regarding the variation of extracellular matrix
proteins, perlecan, fibrillin 1 and biglycan were downregulated on the
Table 1
Characteristics of the reviewed studies.
Article title Author Year Cell type Culture Technique Objectives
Conditioned media from AICAR-treated skeletal muscle cells
increases neuronal differentiation of adult neural
progenitor cells
Youl et al.24 2019 L6 (rat) Culture Tandem mass tag Comparative analysis between AICAR-
treated (AMPK agonist) vs. untreated
skeletal muscle cells










and healthy muscle cells
Mining the secretome of C2C12 Muscle cells: Data dependent
experimental approach to analyze protein secretion using
label-free quantification and peptide based analysis.
Grube et al.26 2018 C2C12
(mouse)
Culture MS and label-free
quantification







Secretome profiling of primary human skeletal muscle cells. Hartwig et al.6 2014 Human
primary
muscle cells
Culture MS and label-free
quantification
In-depth analysis of the secretome identifies three major







Culture MS and label-free
quantification
Comparative analysis between
nanovesicles vs microvesicles content.
Proteomic identification of secreted proteins from human







Culture MS and label-free
quantification
Comparative analysis between strength
training patient biopsies vs. untrained
individuals.
Increased Secretion and Expression of Myostatin in skeletal
muscle from extremely obese women.
Hittel et al.30 2009 Human
primary
muscle cells
Culture SILAC Comparative analysis between
extremely obese vs. Healthy nonobese
women.
Comparative proteomic analysis of the insulin-induced L6
myotube secretome.
Yoon et al.31 2009 L6 (rat) Culture MS and label-free
quantification
Comparative analysis of insulin treated
vs non treated myotubes.
Identification of Differentially Regulated Secretome
components during skeletal myogenesis.
Chan et al.32 2011 C2C12
(mouse)
Culture SILAC
Proteomic Analysis of C2C12 Myoblast and Myotube






Culture MS and label-free
quantification
Comparative analysis of the proteins
present in myotubes vesicles vs.
Myoblasts vesicles.
Muscle tissue as an endocrine organ: Comparative secretome
profiling of slow-oxidative and fast-glycolytic rat muscle
explants and its variation with exercise.
Roca-Rivada
et al.11
2012 Rat muscles Explants MS and label-free
quantification
Dystrophin deficiency leads to disturbance of LAMP-1-
vesicle-associated protein secretion.
Duguez et al.34 2013 H–2K (mouse) Culture SILAC Comparative analysis between wild-
type vs. Dystrophin-deficient
myotubes.
Quantitative analysis of the secretion of the MCP family of






Secretome Analysis of Lipid-Induced Insulin Resistance in






Culture MS and label-free
quantification
Comparative analysis of insulin-
resistant vs. healthy skeletal muscle
cells.
Proteomic analysis of secreted proteins from skeletal muscle
cells during differentiation.




Proteomic Analysis of the Palmitate-induced myotube
secretome reveals involvement of the annexin A1-formyl
peptide receptor 2 (FPR2) pathway in insulin resistance.
Yoon et al.38 2015 L6 (rat) Culture MS and label-free
quantification
Comparative analysis of insulin-
resistant vs. healthy skeletal muscle
cells.
Proteomic Analysis of Tumor Necrosis Factor-Alpha (TNF-
α)-induced L6 myotube secretome reveals novel TNF-
α-dependent myokines in diabetic skeletal muscle.
Yoon et al.39 2011 L6 (rat) Culture MS and label-free
quantification
Comparative analysis of (TNF-
α)-induced insulin resistant vs. wild
type skeletal muscle cells.
Identification of Secreted Proteins during Skeletal Muscle
development.
Chan et al.40 2007 C2C12
(mouse)
Culture MS and label-free
quantification
A. Florin et al. Osteoarthritis and Cartilage Open xxx (xxxx) xxxcontrary to periostin and collagen IV(α2). About the cytokines and
growth factors, only macrophage colony-stimulating factor 1 was
downregulated.25
The alcohol dehydrogenase [NADP (þ)], chymotrypsinogen B, and
protein disulfide isomerase A3 are 3 enzymes which were found to be
more secreted by atrophied skeletal muscle cells. Delta-aminolevulinic
acid dehydratase, Obg-like ATPase 1, peroxidasin homolog were found
to be less secreted.25
TIMP2 was less secreted and serpin A3n was more secreted by atro-
phied skeletal muscle cells. This serpin is localized around the myofiber
and is an extracellular inhibitor of proteases such as granzyme B, trypsin,
chymotrypsin, cathepsins G/B/L and leucocyte elastase. Follistatin is
another protein which is more expressed during skeletal atrophy.25
3.5. Insulin stimulation
A total of 27 proteins were regulated by insulin stimulation with 14
up- and 13 downregulated proteins. Four extracellular matrix protein are4
found to be regulated by insulin in the secretome of skeletal muscle cells.
The collagens V (α2) and III(α1) and calcyclin (formerly known as Protein
S100-A6) are downregulated while collagen VI(α1) is upregulated.31
Some cytokines and growth factors were also regulated by insulin.
FSTL1, IGF-2, IGFBP6 and bone morphogenetic protein 1 (BMP1) were
downregulated by insulin stimulation.31 Finally, only one matrix metal-
loproteinase (MMP 2) was upregulated by insulin. On the contrary,
TIMP-2 is downregulated by insulin31 while plasminogen activator in-
hibitor (PAI1, also known as serpin E1) and serpin H are increased.56,31
3.6. Insulin resistance
Twenty-six proteins were over-secreted and 150 down-secreted in the
secretome of insulin-resistant muscle cells, for a total of 176 regulated
proteins (fig. 4). Most of the ECM proteins were downregulated under
insulin resistant conditions. Indeed, the expression of collagens I, III, IV,
V, VI, XV and XVIII,41 but also laminin, perlecan, nidogen, fibronectin
and periostin, by insulin resistant muscle cells was reduced compared to
Table 2
Summary of recent mass spectrometry-based studies carried out on human skeletal muscle cells to identify secretome components. Classically secreted proteins contain a signal sequence, unlike non-classically secreted
proteins.







Basement membrane-specific heparan sulfate




Classical ↑ ↑ ↓ ↓ 6,27,26,28,31,33,36,37,40
Biglycan collagen fiber assembly Classical ↑ ↓ ↓ 25,40,27,28,26,6,35–38
Collagen I(α1, α2), II(α1), III(α1), IV(α1,α2,α3),
V(α1,α2,α3), VI(α1,α2,α3), VII(α1), VIII(α1),




Classical III(α1), XVIII(α1) ↓
I (α1), II(α1), V















Decorin affects the rate of fibril formation Classical ↑ ↓ 27,28,26,6,35,36
Dystroglycan laminin and basement membrane
assembly, cell survival and
migration
Classical ↑ ↓ 27,28,26,33,35,36,38,39
Extracellular matrix protein 1, 2 Angiogenesis, Biomineralization,
Mineral balance, Osteogenesis
Classical 2 ↓ 29,28,6,34–36,39
Fibrillin 1, 2 Structural component of
microfibrils
Classical 1 ↑ 1↓ 25,27,28,26,6,35,36
Fibromodulin affects the rate of fibril formation Classical ↑ ↓ 36,27
Fibronectin Cell adhesion, cell shape Classical ↑ ↓ 32,29,27,28,6,34,36–39,24
Fibulin 1, 2, 5, 7 cell–cell interaction, cell
migration, ECM remodelling
Classical 1 (isoform C) ↓
1 (isoform D), 2
(isoform B), 5↑
1, 2, 5 ↓ 31,27,28,26,6,33,32,35,36,39
Glypican 1, 6 Role in skeletal muscle
differentiation
Classical 1↑ 1↓ 29,27,28,6,33,35,37,39,40
Laminin α (1, 2, 3, 4, 5), β (1, 2), γ (1,2) Classical α5, α2, β2 ↓ α(4,5), β1, γ1↓ 6,27,28,30,33,35–37
Latent-transforming growth factor beta-binding protein
1(S, L), 2, 3, 4
growth factor binding Classical 3↑ 1, 2, 3, 4↓ 6,26–28,35,36
Lumican Collagen binding Classical ↓ 6,28,29,36
Matrilin 2, 3 involved in matrix assembly Classical 2↓ 26–28,35,36
Matrix Gla Protein Classical 27,33,35,36
Mimecan Induces bone formation in
conjunction with TGF-β-1 or TGF-
β-2.
Classical ↓ ↓ 26,27,31,32,35,36
Moesin connection cytoskeletal structure
- plasma membrane
↑ 6,27,40,28,29,31,34–36,38,39
Nidogen 1, 2 Classical 1,2↓ 6,26–28,33,35,36,38–40
Periostin cell adhesion Classical ↑ ↑ ↓ 6,25–28,35,36
Prolargin Classical ↑ ↓ 26,27,36
Protein S100 (A4, A6 (calcyclin), A11, A13, A16) Classical A6↓ 6,28,30,33–36,38,39
Proteoglycan 4 Role in joint lubrication ↑ 6,27,35
Secreted protein acidic and rich in cysteine (SPARC) Regulates cell growth, binds
calcium and copper
Classical ↑ and ↓ ↑ ↓ 6,26,36–40,
27–32,34,35
Sushi, von Willebrand factor type A, EGF and pentraxin
domain-containing protein 1
cell attachment process Classical ↓ ↓ 6,35,37
Syndecan 2, 4 Classical 27,28,31–33,36
















Table 2 (continued )







proteoglycan that bears heparan
sulfate
Tenascin C, XB, X Cell adhesion Classical C ↑ ↓ 6,26–28,30,35,36
Vitronectin Cell adhesion and spreading
factor
Classical 6,36







Anamorsin (Ciapin 1) Apoptosis, metal binding Non-
classical
↑ 28,31,32,35,36
Angiopoietin 1, 4 angiogenesis, cell proliferation,
adhesion and migration
Classical 1↑ 4↓ 27,28,35,36
Bone morphogenetic protein 1, 4 Cytokine, growth factor,
protease, metalloprotease
Classical ↓ 1 ↓ 26–28,30,35,36
Brain derived neurotrophic factor regulates skeletal muscle
metabolism
Classical 28,36
C–C motif chemokine 2, 3, 5, 7, 8, 9 cytokine, inflammatory response,
chemotaxis
Classical 2↑ 2, 7, 8↑ 2↑
9↓
6,27,28,30,35,36




Classical ↑ ↓ 26,27,35,36
Complement C1q tumor necrosis factor-related protein 1, 3, 5 Classical 3, 5↑ 1, 3 ↓ 26–28,33,35–37
Connective tissue growth factor Cell adhesion, DNA synthesis,
growth factor activity
Classical ↑ ↓ 6,26–28,35,36,38,39
C-X-C motif chemokine (CXCL) 1, 2, 5, 6, 10, 12, 16 Cytokine, growth factor Classical 5↓ 1, 5↑ 6,27,28,32,35,36
Fibroblast growth factor 17, 21 Mitogenic and cell survival
activities
Classical 21↑ 27,30–32,35,36
Follistatin-related protein 1, 3 Heparin binding, modulate
action of some growth factors
Classical 1 ↓, 3 ↑ ↓ 1↓ 6,26,37–39,27–29,31,32,34–36
Galectin 1, 3, 9 regulation of cell proliferation
and migration þ bind galactose
Classical 1↑ 1, 3↑ 1↑ 9↑ 6,26,39,40,27,28,30,34–38
Glucose-6-phosphate isomerase Cytokine, growth factor,
isomerase
Classical ↑ 6,24,39,26–29,34–36,38
Granulins Cytokine, role in inflammation
and tissue remodeling
Classical ↓ 26–28,35,36
Granulocyte colony-stimulating factor cytokine, growth factor, role in
hematopoiesis
6
Gremlin 1 Cytokine Classical 28,33,35,36
Growth/differentiation factor 8 (myostatin), 11, 15 Regulates food intake, energy
expenditure and body weight
Classical 11↓ 27,28,30,35,36
Hepatocyte growth factor Mitogen for hepatocytes cells,
growth factor
Classical ↓ 27,35,36
Hepatoma-derived growth factor Growth factor, repressor Non-
classical
↓ ↑ 37,39




B1 ↑ and ↓ 27,32,35–37
Insulin-like growth factor 1, 1A, 2 Classical 1,2↑ 2↑ ↓ 1↓ 26,27,30,34–36
Insulin-like growth factor binding protein(IGFBP) 2, 3, 4,
5, 6, 7
regulation of cell proliferation Classical 2↓
4↑
5↑ and ↓
↓ 2, 5, 6, 7↓
4 ↑ and ↓
6,26,39,40,27,28,31,32,35–38
Interleukin 1β, 2, 4, 6, 7, 8, 10, 13, 17A, 25, 34 Classical 6,28,35,36
Macrophage colony-stimulating factor 1 Cytokine, growth factor Classical ↓ 6,25,26,28,29,35,36
Macrophage migration inhibitory factor cytokine, isomerase, immunity Classical 6,27,38,39,28,29,31–33,35–37

























Placenta growth factor angiogenesis, differentiation Classical 28,3536
Platelet-derived growth factor A, C Developmental protein, mitogen,
growth factor
Classical A, C↑ C ↓ 27,35,36
Prosaposin (sulfated glycoprotein 1) Lipid metabolism, growth factor
activity
↑ ↑ 6,26–28,31,35–37
Secreted frizzled-related protein 2, 4 Developmental protein,
regulation of cell growth and
differentiation
Classical 2 ↓ 6,27,35,36
Stromal cell-derived factor 1, 2 cytokine, growth factor,
chemotaxis
Classical 27,28,35,36
Transforming growth factor β (1, 2, 3) Multifunctional proteins Classical 1, 2, 3↑ 2↓ 26–28,35,36
Tumor necrosis factor α (TNF-α) Cytokine 6,28
Vascular endothelial growth factor A, C, D growth factor, angiogenesis,
mitogen, differentiation
Classical A, D↓ 35,36







6-phosphogluconate dehydrogenase, decarboxylating Oxydoreductase ↑ 6,26,29,32,34–36,38,39
6-phosphogluconolactonase Hydrolase Classical ↑ 6,29,31,32,34–36,38
A disintegrin and metalloproteinase with thrombospondin
motifs (ADAMTS) 1, 2, 4, 5, 6, 7, 9, 10, 12, 19
cell migration, inflammation,
development
Classical 1↑ 1, 2, 5, 7, 12↓ 27,28,32,35,36
Adenosylhomocysteinase Hydrolase ↓ 6,29,33–36,39
Alcohol dehydrogenase [NADP( þ )] Oxidoreductase ↑ ↑ 6,25,26,29,34–36
Aldo-keto reductase family 1 member A4, C1, C2, C3 Oxidoreductase Non-
classical
A4 ↓ 6,29,32,35,36








Arylsulfatase A, B, K Hydrolase Classical A↓ 28,29,36
ATP synthase subunit beta, mitochondrial Production of ATP from ADP ↑ ↑ 31
Carboxypeptidase A4, D, E, Q Carboxypeptidase, Hydrolase,
Metalloprotease, Protease
Classical E↑ E, Q↓ 26,28,33,35,36,38
Cathepsin A, B, D, H, L1, Z, O Hydrolase, Protease, Thiol
protease
Classical D, L1, O, Z, ↑ D↑
B, Z, L1↓
L1, O ↓ 6,26,38,39,27–29,31,32,34–36
Chymotrypsinogen B Hydrolase, Protease, Serine
protease
Classical ↑ ↑ 25,27,35,36
Creatine kinase B-type, M-type Kinase, Transferase B↑ B↑ 6,11,26–29,34–36
Delta-aminolevulinic acid dehydratase Allosteric enzyme, Lyase Non-
classical
↑ ↓ 6,25,29,31,32,34–36
Dipeptidyl peptidase 1, 2, 3, 4, 8, 9 Aminopeptidase, Hydrolase,
Protease
Classical 2↑ 6,26–29,35,36,38,39
Disintegrin and metalloproteinase domain-containing
protein (ADAM) 9, 10, 12, 15 17, 19
Role in tumorigenesis and
angiogenesis
Classical 10, 12, 19 ↓ 28,35,36,39
Extracellular superoxide dismutase [Cu–Zn] Antioxidant, Oxidoreductase Classical ↑ ↓ 6,26,27,35–37
Farnesyl pyrophosphate synthetase Transferase ↑ 6,29,32–36





Fibroblast growth factor receptor 1, 4 Kinase, receptor, transferase Classical 4↑ 28,36
Fructose-biphosphate aldolase A, B, C Lyase involved in glycolysis A↑ A↑ A↑ 6,11,27,29,32–34,37–39
Glutathione S-transferase A4, MU1, MU2, ω-1, P1, alpha
3
Oxidoreductase, transferase Classical P1, ω-1↑ 6,11,36,38,39,26,28,29,31–35
Glutathione synthetase Ligase Non-
classical
↓ 6,26,29,34,36
Glyceraldehyde-3-phosphate dehydrogenase inhibit cell spreading, glycolysis Non-
classical
↓ ↑ 6,11,30–32,34–36,40
Glycerol 3 phosphate dehydrogenase 11,36
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Glycogen phosphorylase, liver form, muscle form Allosteric enzyme,
Glycosyltransferase, Transferase
Muscle↑ 6,11,26,29,34,36
Histidine triad nucleotide-binding protein 1 Hydrolase, role in apoptosis and
transcription
↓ 28,35,36,38
Hypoxanthine-guanine phosphoribosyltransferase Glycosyltransferase, transferase ↓ ↑ 29,31,32,35,36
Inosine triphosphate pyrophosphatase hydrolase, magnesium binding Non-
classical
26,31,35,36
Inositol monophosphatase 1, 2 Hydrolase Classical ↑ 6,26,29,34–36
Inositol-3-phosphate synthase 1 Involved in myo-inositol
biosynthesis
↑ 26,34,36
Lipoprotein lipase Lipid metabolism, hydrolase Classical ↓ 27,35,36
Mannan-binding lectin serine protease 1 Role in immunity Classical ↑ 25,26,35,36
Matrix metalloproteinase 2, 9, 14, 19 Regulation of cell migration,
metalloproteinase, breakdown of
ECM
Classical ↑ 2, 9, 19↓ 27,28,31,35,36,39,40





Obg-like ATPase 1 ATP hydrolysis ↑ ↓ 25–28,34,36
Peptidyl-prolyl cis–trans isomerase A, B, C, D, H, like 1,
CWC27 homolog, FKBP (1, 3, 4, 9)
accelerate the folding of proteins Classical A, B, C↑ FKBP9 ↓ 6,11,36–39,26–28,31–35
Peroxidasin homolog Peroxidase activity and role in
ECM formation
Classical ↓ 6,25–27,35,36
Peroxiredoxin 1, 2, 4, 5, 6 Protecting cells from free-radical
damage
Classical 1, 2 ↓ 1, 5, 6↑ 4 ↑ and ↓ 6↑ 6,11,38,39,27,29,31–36
Phosphoglycerate mutase 1, 2 Hydrolase, isomerase 2↑ 2↑ 6,11,39,28–30,32,34–36,38
Phospholipase A1 member A, A2 activating protein, D3 Hydrolase, Protease, Serine
protease
Classical A1A↓ 26,27,33,35,36
Procollagen C-endopeptidase enhancer 1 collagenase enhancer Classical ↓ 6,27,31,32,35,38–40
Prolyl endopeptidase Role in tissue remodeling,
fibrosis, inflammation
26,29,33,35,36
Proteasome subunit β (type 1, 2, 3, 4, 5, 6, 8), α (1, 2, 3,







β type (4, 5) ↓ β6, β8↑ 6,11,27,31,32,34–36,38
Protein disulfide isomerase Classical ↑ ↓ 11,35,36,38,39
Protein disulfide-isomerase A (3, 4, 5, 6) chaperone, isomerase, Classical A3, A6↑ A3↑ 3↑ A6↓,
A3, A4↑
6,11,37–39,25,27,28,31,32,34–36





Puromycin-sensitive aminopeptidase involved in cell growth and
viability
↑ 6,34,36,38,39
Pyridoxal phosphate phosphatase involved in mitosis and
cytokinesis
27,35,36




Secretory leucocyte protease inhibitor 36





Spermidine synthase Transferase Non-
classical
↑ 31,32,34–36
Sulfhydryl oxidase 1, 2 Classical 6,26–28,35,36
Superoxide dismutase [Cu–Zn] Antioxidant, Oxidoreductase Non-
classical




















Tissue-type plasminogen activator Tissue remodeling and
degradation
Classical ↑ 26,27,35,36
Transketolase Transferase, calcium and
magnesium binding
6,28,29,34–36,38,39
Triosephosphate isomerase Isomerase involved in
gluconeogenesis and glycolysis
↑ 6,11,36,38,39,26,28–30,32–35
Ubiquitin carboxyl-terminal hydrolase 17-like protein D Protease, hydrolase, thiol
protease
↓ 25
Ubiquitin-conjugating enzyme E1-like 2 (isoform CRA_a),
E2 (D1, D2, L3, K, N, Z, variant 1 et 2)
Transferase Non-
classical
E1-like 2 ↓ E2 variant 1, K,
N↑
26,27,31,32,34–36
α, β, γ enolase lyase α, γ ↑ α, β, γ↑ α↑ α ↑ 6,11,38,39,26,28,29,32–36
α, β-mannosidase Classical β↓ 6,26,36











Cystatin B, C cysteine protease inhibitor Classical C↑ C↓ 6,26,39,40,27,28,31,32,35–38
Metalloproteinase inhibitor (TIMP) 1, 2 Cytokine, growth factor,
metalloendopeptidase inhibitor
Classical 1, 2↑ 1↓ 1↓ 2↓ 2↓ 6,25,35–39,26–32,34




↑ ↑ and ↓ ↑ ↑ 6,11,28,29,35–39
Serpin A6, A8 (angiotensinogen), A11, A3N Regulator of blood pressure, body
fluid and electrolytes
homeostasis
Classical A3N↑ A6↓ 25,28,36
Serpin B1 (Leukocyte elastase inhibitor), B2
(Plasminogen activator inhibitor 2), B6, B9




B2↓ B1, B6↑ 6,27–29,32–36,39
Serpin C1 (Antithrombin-III) Inhibitor of serine protease,
regulation of cell migration
Classical ↑ ↓ 6,27,29,31,32,35
Serpin E1 (Plasminogen activator inhibitor 1), E2 Inhibitor of serine protease,
regulation of cell migration
Classical E1, E2↑ E1↑ E1↑
E2↓
6,26–29,35,36,40
Serpin F1 (pigment epithelium derived factor (PEDF)) Inhibitor of serine protease,
regulation of cell migration
Classical ↓ 6,26–29,35–37,40
Serpin G1 (Plasma protease C1 inhibitor) Inhibitor of serine protease,
regulation of cell migration
↓ 6,26,27,30,34
Serpin H1 Inhibitor of serine protease,
regulation of cell migration
Classical ↑ ↑ and ↓ 6,28,31,32,35,36,38,39
Tissue factor pathway inhibitor Anti-thrombic action and
associates lipoproteins in plasma
Classical ↑ ↓ 27,35,36
α(1,2)-macroglobulin Protease inhibitor, serine
protease inhibitor
Classical 1, 2↑ ↓ 6,27–29,34,35







Actin, aortic smooth muscle 6,11,28,29,35,36
Actin, cytoplasmic 1, 2 6,28,29,32,36,39
Actin, α cardiac muscle 1 ↑ 6,11,28,29
Actin, α skeletal muscle ↑ ↑ 6,11,28,29,34–36,39
Actin-related protein 2, 3 2↑ 6,28,29,34–36





Cell division control protein 42 homolog Differentiation, neurogenesis non-
classical
31,32,35,36




1 ↓ 2↑ 1 ↑ 6,11,38,39,26,28,31–36





Destrin Actin-depolymerizing protein 6,31,32,35,36
















Table 2 (continued )









Ezrin Cell shape 6,28,29,33,35,36
F-actin-capping protein subunit α (1, 2), β actin capping, actin binding 6,29,35,36
Filamin A, B, C Actin binding C↑ 6,11,28,29,33–36,38,39
Gelsolin actin capping, actin binding Classical ↑ 6,24,38,26–29,33–36
Myomesin 1, 3 Major component of the
vertebrate myofibrillar M band
11,36
Myosin 1, 3, 4, 6, 7, 8, 9, 10 Role in cytokinesis, cell shape,
secretion and capping
3↑ 6,11,39,28–30,33–36,38
Myosin binding protein C, fast type cell adhesion 11,30
Myosin light chain 1, 2, 3, 4, 6B, 12B, 1/3 Muscle contraction, motor
activity, calcium binding
1, 4, 6B, 12B↑ 6,13,28,29,31,35–37,40,29
Myosin regulatory light chain 2, skeletal muscle isoform,
4, 12B
Contractile protein 2↑ 6,11,28,34–36,38,39
Myotilin Involved in a complex of actin
cross-linking proteins
11
Palladin Role in cell morphology, motility,
cell adhesion
28,29,35,36





Plectin actin binding ↑ 6,11,28,33,35,36
Profilin 1, 2 Actin binding Non-
classical
1 ↓ 1↑ 1↑ 6,11,28,31,32,34,36,38,39
Titin Key component in the
functioning of striated muscle
↑ 11,29,30,33–36
Transgelin 1, 2 Non-
classical
2 ↓ 1, 2↑ 6,28,31–35,38,39
Tropomyosin α (1, 3, 4), β (1, 2) actin-binding Non-
classical
α1, β ↑ β ↓ β↑ β 2 ↑ 6,11,30–32,34,35,38,39
Troponin I (slow skeletal muscle), C (slow, skeletal and
cardiac muscle), T
inhibitory subunit of troponin,
muscle protein, actin binding
I, C, T↑ 6,11,34–36,39
Tubulin α (A,4A, B), β (2A, 3, 4B, 5, 6) Non-
classical
α4A↑ α1A↑ 6,26,32–36,39
Vimentin cytoskeletal protein Non-
classical
↑ ↑ ↑ 6,11,36,38–40,28–35
Vinculin Actin binding, cell adhesion ↑ ↑ 6,28–30,34–36,38,39
α-actinin 1, 2, 3, 4 actin binding 3, 4↑ 6,24,28,29,34–36,38,39







14-3-3 protein β/α, γ, ζ/δ, ε, η, θ Non-
classical
ε↑ 6,28,29,32–36,38,39
ADAMTS-like protein 1, 2, 3, 4 Hydrolase Classical 3↑ 2↓ 27,28,35,36
Adapter molecule crk cell adhesion, spreading,
migration
6,26,28,35,36




Agrin Developmental protein Non-
classical
↓ 27,28,35,36
Alpha-1-acid glycoprotein 1 Transport Classical ↑ 25





















involved in exocytosis, regulation




AP-1 complex subunit β1, γ1, σ (1, 2), μ1 Transport, protein transport Non-
classical
28,31,35,36
Apolipoprotein B-100, D, E Lipid metabolism and transport Classical B-100↑ E↑ 6,27,28,35,36
Basal cell adhesion molecule Blood group antigen, receptor 6,26,29
Brain acid soluble protein ↑ 28,33,38,39
Cadherin 2, 5, 11, 13, 15 (M-cadherin), 23 cell adhesion Classical 23 ↑ 11, 13, 15↑ 2, 15↑ 15↑ 2, 11, 13, 15↓ 6,26,39,27–29,33–36,38
Calcium/calmodulin-dependent protein kinase type 1 Cell cycle, differentiation,
neurogenesis
27,35,36
Calmodulin mediates a large number of
enzymes
↑ 6,11,28,33,34,36,39
Calpastatin inhibition of calpain, may be
involved in protein degradation
in muscle
28,35,36,39
Calreticulin calcium binding chaperone Classical ↓ 6,11,27,28,34–38
Calsequestrin 1, 2 calcium storage Classical 2↑ 6,26,27,33,36,38
Calsyntenin 1, 2 Classical 1↓ 6,26–28,35,36,38
Calumenin Metal-binding, calcium binding Classical 6,27–29,34–36,38,39
Cartilage intermediate layer protein 1, 2 Classical 1, 2↑ ↓ 26,27,36
Catenin α1 Association with cadherin ↑ 25,28,35,36
Cellular nucleic acid-binding protein Single-stranded DNA-binding
protein
↓ 31
Chloride intracellular channel protein 1, 4 transport, chloride transport Non-
classical
4 <-> 4↑ 6,26,31–36
Chordin Developmental protein Classical ↓ 27,35,36
Clusterin apoptosis, immunity Classical ↑ ↑ and ↓ 38,39
Coatomer subunit α, β, δ, ε Transport Classical 6,28,30,32,34–36
Coiled-coil domain-containing protein 80, 126 Promotes cell adhesion and
matrix assembly
Classical 80↑ 6,27,28,36,38,39
Complement component 1, C3, C4 (A, B) Immune response C3,C4B↑ 6,28,30,35,39
Complement factor B, D, H Immune response Classical H ↑ ↑ H↓ 6,25–28,30,35,36
Cytochrome C 6,11,27,28,35,36
Drebrin Actin binding, differentiation,
neurogenesis
6,28,35,36,39
Elongation factor 1 (α1, β, δ, γ) 2 Factor elongation 2↑ 1α1, 1γ, 1,β, 2↑ 6,11,36,38,39,26–29,32–35
Endoplasmin Chaperone Classical ↑ 6,27,28,31,34–36,38
Ephrin type-A receptor 1, 2, 4, 7 cell adhesion, neurogenesis Classical 2↓ 6,27,28,33,36
Exostosin 1, 2 protein glycosylation 26–28,35,36
Fascin actin binding ↑ 6,32,34–36,38
Fatty acid-binding protein, heart Transport of lipids ↑ 11,28,35,36
Follistatin activin antagonist, inhibitor of
FSH biosynthesis
Classical ↑ ↑ ↓ 25,26,35,36
Four and a half LIM domains protein 1, 2, 3 Metal binding Non-
classical
6,11,31,32,35,36,38
Galectin-3-binding protein Cell adhesion Classical ↓ 25–27,35,36
Glucosidase 2 subunit β Metal binding, calcium binding Classical ↑ 6,28,29,34,36
Growth factor receptor-bound protein 2 link between growth factor and
RAS signaling pathway
6,26,35,36
Heat shock 70 kDa protein 1A/1B, 1 like,2, 4 ATP binding, nucleotide binding 2↑ 6,11,26,29,34–36,38,39
Heat shock protein beta(1, 2, 3, 6, 7) Chaperone 2↑ 1 ↑ and ↓ 6,11,28,29,33–36,38,39
Heat shock protein HSP 90 (α, β) Chaperone α↑ α↑ 6,36–38
Heme-binding protein 1, 2 6,28,29,35,36
High mobility group protein HMGI-C Cell cycle, cell division, growth
regulation
28,35,36
Hypoxia up-regulated protein 1 role in cytoprotection triggered
by oxygen deprivation
Classical 27,28,36
Importin 5, 7, 9 transport nucleaire 6,33,35,36
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Integrin α (1, 3, 5, 6, 7), β (1, 5) cell adhesion, integrin, receptor,
cell adhesion
Classical α3, 5, 7↓
β1, 5 ↓
27,28,30,33,35,36
Lactadherin angiogenesis, cell adhesion Classical 27,28,35,36,38
Leukemia inhibitory factor receptor Signal transducing molecule Classical ↓ 27,36
L-lactate dehydrogenase A chain, B chain Pyruvate fermentation to lactate Non-
classical
A ↓ A↑ A↑ 6,11,38,39,24,26,28,31,32,34–36
Lipopolysaccharide-binding protein Innate immune response Classical ↑ 25,36
Low-density lipoprotein receptor Binds and transport LDL Classical 26,36,38
Lysosome-associated membrane protein 1, 2 1↑
2↓
26,36
Lysyl oxidase homolog 1, 2, 3, 4 Active on elastin and collagen
substrates
Classical 1↑ ↑ 1, 3, 4↓ 25–28,35,36
Macrophage-capping protein actin capping and binding Classical 6,27,28,33,34,36
Meteorin-like protein Hormone induced by exercising
and promotes energy expenditure
Classical 27,35,36









Myc box-dependent-interacting protein 1 Differentiation, endocytosis ↑ 6,27,28,33–36,38
Myoferlin involved in muscle contraction ↑ 33–36
Myoglobin oxygen transport Non-
classical
11,26,30,34–36
Myotrophin regulation of the growth of actin
filaments
6,28,35,36,38
NAC α domain containing Protein transport Classical ↑ 32,40





Neogenin cell adhesion in myogenesis Classical ↓ 27,28,36
Nephronectin Cell adhesion, spreading and
survival
Classical ↓ 27,33,35,36
Neudesin Promotes cell proliferation and
neurogenesis
Classical 27,35,36
Neural cell adhesion molecule 1 Cell adhesion Classical ↑ ↓ 6,26,39,27–29,33–36,38
Neuropilin 1, 2 Angiogenesis, differentiation,
neurogenesis
Classical 1, 2↓ 26–28,33,36
Nuclease-sensitive element-binding protein 1 mitogen, activator, repressor Classical 28,35–37
Nucleobindin 1, 2 Calcium binding, may have a role
in calcium homeostasis
Classical 1↑ 1, 2↓ 1 ↓, 2 ↑ 24,26–28,34–36,38,39
Nucleophosmin cell proliferation, regulation of
tumor suppresors
↑ 11,32,35,36
Olfactomedin-like protein 2A, 2B, 3 extracellular matrix organization Classical 2A↑ 2B, 3↓ 26–28,35,36
Parvalbumin alpha involved in relaxation after
contraction
11,27,35
Phospholipid transfer protein Lipid transport Classical ↓ 6,26–28,33,36
Plastin 3 Actin binding 26,28,33,35,36,39
Plexin A (1, 2, 3, 4), B2 Classical B2↓ 27,33,35,36
Poly(rC)-binding protein 1, 2, 3 DNA binding, RNA binding Non-
classical
6,31,32,35,36
Programmed cell death 5, 6-interacting protein apoptosis, cell cyle, cell division,
transport
5↓ 26–28,33,35,36,39
Proliferating cell nuclear antigen DNA binding Non-
classical
26,28,31,32,35,36
















Protein jagged-1 Inhibits myoblast differenciation Classical 28,36




Protein RCC2 mitosis and cytokinesis 35,36
Protein VAC14 homolog phosphatidylinositol biosynthetic
process and signal transduction
↑ 31
Protocadherin-1, gamma C3, 18, 19, beta 14, Fat 4 cell to cell adhesion and
interaction processes
Classical 19, Fat 4↓ 27,35,36





Ras-related protein Rab 5A, 14, 35 Protein transport, transport Non-
classical
29,33,35,36
Reticulocalbin 1, 2, 3 Calcium, metal binding Classical ↓ 6,26,28,34–36,39
Reticulon 2, 4 Neurogenesis 4↑ 33–36





Semaphorin 3(A,B, C, D, E), 4(B, C), 5A, 6(A, B), 7A Role in differenciation,
inflammation and neurogenesis
Classical 3A, 3D, 3E, 6A
(isoform 1)↑
7A↑ and↓
3 (A, B), 4B,
4C, 6A↓
26–29,35–37
Septin 2, 7, 9, 11 Cell cycle, cell division,
differentiation, mitosis
11↑ 26,28,34–36,38
Serotransferrin Iron transport ↑ 11
SH3 domain-binding glutamic acid-rich protein 6,30,31,35,36
Slit homolog 2 protein Differentiation, neurogenesis Classical ↓ 27,36
Spondin 2 cell adhesion, immunity Classical ↓ 6,26,27,31,32,35
Stanniocalcin 1, 2 Stimulates renal phosphate
reabsorption
Classical 6,28,31,32,35,36,38
Stathmin 1, 2 Regulation of the microtubule
filament
1 ↑ 6,30–32,35,36,39
Sterile α motif domain-containing protein 3 ↓ 32




Talin 1, 2 connections in the cytoskelettal
structure
28,33,35,36,38
Telethonin Muscle assembly regulating
factor
11
Testican 1, 2 Neurogenesis Classical 2↑ 6,25–28,36





Thrombospondin 1, 2 mediates cell to cell and cell to
matrix interactions
Classical ↑ 1↑ 6,26–28,31,32,35–37
Transcobalamin 2 Vitamin B12 binding, transport
protein
Classical ↓ 26,27,35,36,39
Transcription elongation factor B polypeptide 2 (Elongin-
B)
Transcription factor ↑ 25–28,35,36
Translationally-controlled tumor protein involved in microtubule




Ubiquilin 1, 2, 3 Regulation of protein
degradation
28,35,36
Vacuolar protein sorting-associated protein 26A, 29, 35,
37C VTA1 homolog
protein transporter ↑ 26A, 35↑ 6,26–28,33–36
Vascular cell adhesion protein 1 Cell–cell recognition Classical Isoform 1↑ 27,28,36
Vasorin Classical 6,27,28,36
Vigilin Lipid metabolism Non-
classical
↑ 28,35,36
Vitamin K-dependent protein S Blood coagulation, fibrinolysis,
hemostasis
Classical ↓ 6,26,27,36






















































































































































































































Fig.2. The secretome analysis of skeletal muscle cells after exercising showed
that no proteins were down-regulated and 30 proteins were up-regulated. Pro-
teins were then classified and counted on the basis of their function.
A. Florin et al. Osteoarthritis and Cartilage Open xxx (xxxx) xxx
14that of healthy muscle cells.36,38,39,41
The cytokines and growth factors were also differently expressed in
insulin-resistant muscle cells compared to healthy cells. For example,
FSTL1 and C–C motif chemokine 9 were downregulated in insulin
resistant muscle cells31 while monocyte chemotactic protein-1 (MCP-1)
(also known as C–C motif chemokine 2) was upregulated. Interestingly,
MCP-1 was involved in the recruitment of macrophages into the site of
muscle damage. They also influence the migration of muscle cells during
development.57 MCP-1 activates the extracellular signal-regulated kinase
1 and 2 (Erk ½) leading to myoblast proliferation in response to muscle
injury.35,58,36
Concerning the Insulin-like growth factor, IGF-1 was 3 times less
concentrated in the secretome of insulin resistant muscle cells.36
Furthermore, IGFBP2, IGFBP4, IGFBP5, IGFBP6 and IGFBP7 were all
downregulated in insulin-resistant muscle cells and in patients with type
2 diabetes.36,59 Furthermore, low plasma levels of IGFBP7 was correlated
with the incidence of type 2 diabetes in humans.59
The concentration of BMP1 in the secretome of insulin resistant
skeletal muscle cells was also decreased compared to healthy skeletal
muscle cells.36 Granulin was found in the secretome of skeletal muscle
cells and has many roles including cell growth and anti-inflammatory
Fig.3. The secretome analysis of skeletal muscle cells during myogenesis showed that 40 proteins were down-regulated and 90 proteins were up-regulated. Proteins
were then classified and counted on the basis of their function.
A. Florin et al. Osteoarthritis and Cartilage Open xxx (xxxx) xxxeffects. The secretion of this cytokine was decreased in insulin-resistant
skeletal muscle cells, leading to an increase in the inflammatory
response under insulin-resistant conditions.60,36
In the family of Semaphorins, the Semaphorins 3A, 3B, 4B, 4C and 6A
were all less concentrated in the secretome of insulin resistant muscle
cells compared to healthy muscle cells.36,38,39
The growth/differentiation factor 11 (GDF11) was significantly
decreased in insulin-resistant muscle cells.36 Hepatocyte growth factor
and platelet derived growth factor C are involved in muscle proliferation
and differentiation and are also decreased in the secretome of insulin
resistant muscle cells.61,62 Follistatin, an inhibitor of myostatin49 was
found to be decreased in the secretome of insulin resistant skeletal
muscle cells.
Concerning the enzymes, the secretion of MMP2, MMP9, MMP19 but
also ADAMTS -1, 2, 5, 7 and 12 are downregulated in insulin
resistant muscle cells. On the contrary, the secretion of TIMP-2 is up-
regulated in insulin resistant compared to healthy muscle cells.38,39,36
Regarding the regulation of the enzymatic inhibitors, the secretion of
Serpin A6, E2 and F1 are downregulated in insulin resistant skeletal
muscle cells while Serpin E1 is upregulated.39,38,363.7. Others
The secretion of certain proteins can also bemodified according to the
muscle. Roca-Rivada et al compared a slow-oxidative muscle with a fast-
oxidative muscle to highlight differential expression of proteins. One of
the regulated proteins was the heart fatty acid binding protein (FAPB-3)
which was 3 fold more abundant in the secretome of soleus versus15gastrocnemius muscle.11 This protein is thought to be involved in
intracellular transport of long-chain fatty acids which is consistent with
its upregulation in oxidative muscle. Indeed, type I fibers are predomi-
nant in slow oxidative muscle and uses fatty acids and glucose as fuel to
produce ATP.
4. Discussion
Skeletal muscle is known to secrete proteins and especially myokines
that allow communication in an autocrine, paracrine and endocrine
manner (fig. 5). Some of these secreted proteins and myokines can be
found in the blood or in the urine and can reflect a change in the path-
ophysiological state of an individual. The study of the secretome of
skeletal muscle cells is of great interest to identify a range of candidate
biomarkers from muscle diseases like sarcopenia, allowing early diag-
nosis and appropriate interventions. This review summarizes the data
obtained by proteomic studies of the secretome of skeletal muscle cells or
explants. The advantage of this method is the control of the key param-
eters and the live conditions of cells or tissues. For instance, only 6
conditions have been reported: exercising, myogenesis, dystrophin defi-
ciency, muscle atrophy, insulin-treated and insulin-resistant. Clearly,
insulin-resistance and myogenesis are the two most documented condi-
tions. There is a paucity of published data on the secretome of sarcopenic
muscle.
The interest in insulin expression and signalling within muscle comes
from the fact that skeletal muscle energy supply depends on up to 75% of
the insulin dependent glucose uptake and storage as glycogen. Further-
more, insulin resistance leads to the development of type 2 diabetes,
Fig.4. The secretome analysis of insulin resistant skeletal muscle cells showed that 150 proteins were down-regulated and 26 proteins were up-regulated. Proteins
were then classified and counted on the basis of their function.
A. Florin et al. Osteoarthritis and Cartilage Open xxx (xxxx) xxxwhich is associated with muscle dysfunction and weakness. Several
methods have been used to induce insulin resistance in muscle cells.
Yoon et al induced resistance by addition of TNF-α39 or palmitate38 while
Deshmuk et al used palmitic acid.36 These models drastically influence
the secretome of skeletal muscle cells. Eighteen proteins were regulated
under both conditions (fig. 6). The type 1 collagen III and the type 2
collagen V are the 2 only collagens which are downregulated by these
two treatments. The other proteins down-regulated in these two models
were BMP1, FSTL1, IGFBP6, TIMP2 and NUCB1 while PDIA3, ENO1 and
Serpin E1 (PAI-1) were up-regulated. FSTL1 and IGFBP6 regulate the
action of some growth factors and their decrease may lead to a reduced
regenerative capacity of the muscle. The reduction of TIMP2 secretion
leads to a greater matrix cellular degradation. PDIA3 is also upregulated
by dystrophin deficient cells and during atrophy. This protein has
recently been shown to be a marker of muscle aerobic capacity.65 ENO1
is a key glycolytic enzyme and its expression is increased by insulin
suggesting that ENO1 increase could be a compensatory mechanism to
metabolize glucose in insulin-resistant muscle cells. Serpin E1 is
increased in the plasma of obese and insulin-resistant patient,56 this is
also the case in the secretome of insulin resistant skeletal muscle cells or
after insulin stimulation.31,36 In addition to its role in regulating growth
and metabolism, IGF-1 has also insulin-sensitizing and glucose lowering
actions.36 IGF-1 decreases in insulin-resistant skeletal muscle cells'
secretome leading to this insulin resistant state. Many chemokines (CCL2,16CXCL1 and CXCL5) were up-regulated in insulin-resistant muscle cells,
this may lead to a low-grade chronic inflammation which is a hallmark of
type 2 diabetes.66 Furthermore, patient with type 2 diabetes have MMP-2
levels significantly higher than healthy patient,66 this is in accordance
with the increase of MMP-2 and the decrease of TIMP2 in insulin-treated
muscle cells’ secretome. Interestingly, MMP-2 secretion decrease in the
conditioned media of insulin-resistant skeletal muscle cells leading to a
reduced extracellular matrix component degradation and subsequent cell
migration and tissue remodeling.30,40 Annexin A1 was found to be
down-regulated in insulin-stimulated skeletal muscle cells.38 The
Annexin A1-FPR2 axis plays a protective role in insulin resistance by
mediating leukocyte recruitment and anti-inflammatory effects. This
pathway might be a new therapeutic target for insulin resistance.38
The second most investigated condition is myogenesis. The formation
of myotubes involves multiple steps such as cell migration, recognition,
alignment, adhesion, cell fusion and ECM reorganization. Three pub-
lished papers have been devoted to the study of proteins secretion during
the skeletal muscle development. Interestingly, these studies investigated
the secretome at different stages of muscle development.27 At day 0, 2
and 5 during differentiation for Henningsen et al.27, before differentia-
tion and after 30 h, 72 h and 120 h of differentiation for Ojima et al37 and
finally after 24 h and 120 h of differentiation in the Chang's study.32
Table 2 highlights the proteins that are regulated (up or down) in the
secretome of myotubes (after 120 h of differentiation) and myoblasts
Fig.5. Schematic representation of the secretome of skeletal muscle cells. The stimulation is represented by green arrows and the inhibition is represented by red
crossed arrows. Collagens are represented in blue; proteoglycans and glycosaminoglycans are represented in pink; glycoproteins are represented in orange; growth
factors and cytokines are represented in purple; enzymes are represented in dark green; enzymatic inhibitors are represented in light green and other proteins are
represented in dark gray. MMP: Matrix Metalloproteinase; TIMP: Metalloproteinase inhibitor; IL: Interleukin; IGF: Insulin-like growth factor; FGF: Fibroblast Growth
Factor; GDF: Growth/Differentiation factor; GH: Growth hormone; BMP: Bone morphogenetic protein; ENO: Enolase; IGFBP: Insulin-like growth factor binding
protein; LTBP: Latent-transforming growth factor beta-binding protein; MCK: Muscle creatine kinase; TGF: Transforming growth factor.
Fig.6. Venn diagrams showing the number of differentially regulated proteins between different conditions/pathologies. A. Proteins differentially regulated between
the conditions dystrophin deficiency, atrophy and exercise. B. Proteins differentially regulated between the conditions insulin resistance, myogenesis and insulin
stimulation. C. Proteins differentially regulated between the conditions dystrophin deficiency, atrophy and insulin resistance.
A. Florin et al. Osteoarthritis and Cartilage Open xxx (xxxx) xxx(before differentiation). Interestingly, the secretion of some proteins
resulting from different studies appear to be contradictory. This is the
case for the proteins high mobility group B1, semaphorin 7A, phospha-
tidylethanolamine binding protein 1, IGFBP5 and SPARC. These17differences may be due to the different culture media used in these in
vitro studies to induce the differentiation of myoblasts. These media may
lead to a differential secretion and a variable advance in differentiation of
myoblasts into myotubes. Henningsen et al27 studied the dynamics of the
A. Florin et al. Osteoarthritis and Cartilage Open xxx (xxxx) xxxskeletal muscle cell secretome during differentiation, this method is
useful for understanding which factors are secreted during myogenesis.
They observed that ECM reorganization is critical during differentiation
and is particularly controlled by the TGF-β proteins by promoting the
synthesis of ECM components.27 For example, mimecan (also called
osteoglycin) was downregulated by more than 6 fold during myogenesis
and appeared to decrease the transcriptional activity of muscle creatine
kinase (MCK), which suggests that mimecan may only influence the early
stages of myogenesis.32,67
Furthermore, TGF-β proteins have a role in inhibiting differentiation
of skeletal muscle cells, which is in accordance with the continuous in-
crease of these proteins during the course of differentiation.27 The
growth factors IGF-1 and IGF-2 play also a crucial role during differen-
tiation. IGF-1 is important in the beginning of the differentiation whereas
IGF-2 is essential throughout the differentiation process. They are regu-
lated by IGFBPs. The interactions and regulations of IGFs by IGFBPs are
complex. This is highlighted by variation of IGFBPs production during
differentiation. IGFBP2 decreases and IGFBP4 increases during differ-
entiation whereas IGFBP5, -6 and -7 were not significantly regulated.27
About semaphorins, the dynamics of expression suggest that they mainly
regulate the early phase of differentiation in an autocrine way, except for
semaphorin 7A which increases throughout the course of differentiation.
Furthermore, SEMA3A activates MMP-2 which has a crucial role for ECM
remodeling during differentiation. Indeed, MMP-2 degrades extracellular
matrix, leading to a release of growth factors and signaling molecules
that play a role in activation and proliferation of satellite cells.68 This is in
accordance with the up-regulation of MMP-2, especially during the early
phase of myogenesis. On the other hand, SEMA3A decreases both the
expression and activity of MMP-3. Interestingly, they are a lot of proteins
(54) that are regulated both by myogenesis and insulin resistance (fig. 6).
Insulin resistance leads to an accumulation of adipose tissue resulting in a
rise in circulating adipokines. Some adipokines like resistin leads to lipid
accumulation in skeletal muscle and subsequently to insulin resistance
through activation of protein kinase C.69 Furthermore, the adipokine
resistin were found to impair myogenesis through activation of NF-κB.70
Insulin resistance also decrease skeletal muscle anabolism and so induce
loss of skeletal muscle mass.71 On the contrary, insulin induce myo-
genesis through inhibition of glycogen synthase kinase 3 beta (GSK-3β)
and is mediated by AKT.72 Furthermore, enzymatic inhibitor Serpin E1
and the glycoprotein FSTL1 were downregulated both during myo-
genesis, insulin resistance and insulin stimulation (fig. 6).73
The third condition studied is dystrophin deficiency. Dystrophin
deficient H–2K skeletal muscle cells were extracted from mdx-H2Kb-ts58
(CBA/ca X C57B1/10ScSn-mdx) mice at 1 month of age. The secretome
of the mdx myotubes were compared to wild-type myotubes.34 Inter-
estingly, mdx myotubes secreted twice as much total protein and most of
the secreted proteins were cytoplasmic.34 In addition, fibronectin was
found in higher amount in the conditioned media of mdx muscle cells.
This study demonstrates that dystrophin deficiency impairs vesicle traf-
ficking leading to excess protein secretion and fibrotic deposition.34
Another condition studied in this review was the glucocorticoid-
mediated muscle atrophy. Muscle cell atrophy was induced by adding
106 M dexamethasone in the cell medium for 24 h in serum free con-
ditions. Chronic glucocorticoid (GC) exposure in humans is well known
to result in whole-body insulin resistance and obesity. This occur mainly
through the suppression of osteoblasts’ osteocalcin secretion rather than
GC signaling in the liver or the skeletal muscle.74 Insulin resistance im-
pairs glucose metabolism and high-glucose levels are known to inhibit
myogenesis.71 Interestingly, some proteins are modulated both in the
insulin resistance and in the muscle atrophy models. A decrease in
secretion of perlecan and biglycan were observed in both models.25 The
protein disulfide isomerase A3 increased in the conditioned media of
atrophied skeletal muscle25 and during insulin-stimulated and insulin
resistant conditions. Furthermore, this protein is expressed more by low
capacity compared to high capacity running rats and may be a biomarker
of muscle aerobic capacity. This may be due to differences in insulin18muscle sensitivity.65 It would be interesting to study the mechanism of
action of this protein and its role in these different conditions. Serpin A3n
was found to rise in the serum of mice treated with dexamethasone.25
Serpin A3n may have a protective role towards skeletal muscle through
his antiprotease activity against extracellular proteases.25 This protein
may be a potential biomarker of glucocorticoid-induced muscle
atrophy.25
The last condition reported in this review was secretome modifica-
tion by exercise. The first study compared the secretome of slow-
oxidative (soleus) and fast-oxidative (gastrocnemius) muscle explant
and its variation with endurance exercising.11 The rats where housed in
rodent cages with a running wheel coupled to a turn counter. Rats
running 8 h a day were selected for the secretome study. The control
group (non-exercising) was compared to the exercising group who
performed this endurance exercise during 6 days. As anticipated, the
two muscle types showed different secretome. For example, IL-6 and
FAPB-3 were more abundant in soleus muscle compared to gastrocne-
mius muscle. On the contrary, the protein DJ-1 was secreted in higher
amount in the gastrocnemius muscle compared to the soleus. This
means that exercises can modify the fiber-type of the muscle and so
influence the secretion pattern. The second article mimicked the effects
of exercising by using the AMP-kinase agonist 5-amino-
imidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR). Indeed, AMPK
activation blocks energy-consuming processes and promotes ATP syn-
thesis from glucose uptake, glycosylation and fatty acid oxidation.
AICAR treated mice show decreased fat mass, increase running endur-
ance and muscle mass.24 With these experiments, Youl et al observed
that secretory proteins from AICAR treated skeletal muscle cells could
influence in vitro expression of neuronal differentiation markers, sug-
gesting that exercise-induced secreted proteins from skeletal muscle
may play a role in neurogenesis.24 Interestingly, no proteins are regu-
lated both by atrophy and by exercise. This is not the case for dystro-
phin deficiency and exercise, because 12 proteins were regulated by
these two conditions (fig. 6). This may be a consequence of the damage
or the inflammation induced in the first case by the dystrophin defi-
ciency and in the second case by exercising.75 It is interesting to notice
that ENO1 was upregulated in most of the conditions (exercising, dys-
trophin deficiency, insulin stimulation and insulin resistance). The
upregulation of ENO1 may be an adaptation to better metabolize
glucose during exercising or in the case of exercise intolerance leading
dystrophy.75,76
Another important cytokine with myokine properties is IL-6. IL-6 is a
crucial exercise-induced cytokine that probably mediates the immuno-
regulatory and anti-inflammatory effects of physical exercise.49,77,78
Unfortunately, the detection of IL-6 in the conditioned media of skeletal
muscle cells has not been possible. Indeed, due to the intolerance of
myotubes to serum-free conditions, the incubation was limited to 6 h to
avoid leakage of intracellular proteins, which may result in the inability
to detect low-abundance proteins. It may also be due to the small size of
this protein which is a limitation of the analysis by mass spectrometry. In
conclusion, the up- or downregulation of IL-6 by exercise has not yet been
demonstrated by an in vitro proteomic approach. Currently, no regula-
tion of myostatin (GDF8) in the secretome of skeletal muscle cell has been
demonstrated by mass spectrometric analysis. This protein is a crucial
negative regulator of skeletal muscle growth, modulate adipose tissue
mass and function and is involved in the maintenance of metabolic
homeostasis.
This systematic review has some limitations due to the significant
difference in the methodologies used to study the skeletal muscle
secretome. One main concern is that each research group has employed a
different type of skeletal muscle cell preparation, or different culture
media and different protocols to analyze the secreted proteins. These
differences in methodology complicate objective comparisons between
the studies. For example, in explant cultures, a large part of the proteins
secreted are entrapped in the extracellular matrix, modifying the secre-
tome analysis.79 Other cell types are present within skeletal muscle in
A. Florin et al. Osteoarthritis and Cartilage Open xxx (xxxx) xxxvivo (for instance, fibroblasts and adipocytes) that could influence the
secretome of the skeletal muscle. This is particularly important because
the secretome of infiltrating adipocytes may be largely catabolic and
inflammatory, leading to low grade inflammation within skeletal muscle.
Another drawback of using skeletal muscle cells in vitro is that they are
non-functional. They are not exposed to physiological mechanical strains
that exist in vivo during muscle contraction. Several studies have shown
that contraction influence skeletal muscle cells’ secretome.80 It is
possible to overcome this issue by studying mRNA expression in skeletal
muscle biopsies29 or by exploring the secretome of skeletal muscle ex-
plants.11 Manabe et al developed an in vitro muscle contraction model
based on mouse primary cultured myotubes and this model may enable
the discovery of novel myokines secreted by muscle contraction.81
Furthermore, the quantitative assessment of proteins remains complex
due to their different solubility, binding to other components, size,
length, amino acid sequence and post-translational modifications.
Finally, during the process of proteomic analysis, at least 2 independent
peptides are needed for the unambiguous identification of proteins, but
very small proteins (like cytokines) generate few peptides after trypsi-
nization, leading to a possible exclusion of key proteins from the final
analysis.
In conclusion, the study of the secretome of skeletal muscle cells
highlights novel proteins andmyokines that could be candidate biomarkers
for the diagnosis, prognosis or follow-up of interventions of in muscular
diseases like sarcopenia. Particular attention should be given to proteins
like TNF-α, β-aminoisobutyric acid (BAIBA),82 irisin,83 interleukin 1583,
decorin, myostatin, myonectin,84 meteorin-like 1,85 adiponectin, C-reac-
tive protein CRP, HSP72 and C-terminal fragments of agrin86,87 whichmay
be involved in ageing and inflammatory processes. However, very limited
studies associated with the role of myokines are currently available and
more researches need to first determine and address the expression profile
in muscle development and regeneration. The underlying signaling path-
ways also need to be studied in details. Secretome analysis has generated a
lot of data that could be implemented in big data system and learning
machine, a way currently used in other research field to identify patient
phenotypes, leading to a more personalized treatment.
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